English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Avance Clinical은 4월 23일부터 25일까지 보스턴에서 열리는 세계 고아약 학회에서 임상 우수성을 선보입니다
Apr 20, 2024 18:50 HKT
Avance Clinical 在4月23日至25日波士顿世界孤儿药物会议上展示临床突出成绩
Apr 20, 2024 18:00 HKT
Avance Clinical 在4月23日至25日波士頓世界孤兒藥物會議上展示臨床突出成績
Apr 20, 2024 18:00 HKT
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
Apr 20, 2024 01:00 HKT
DC Healthcare Rides the Wave of Success with New Openings at Publika and Bukit Indah
Apr 18, 2024 19:33 HKT
中国抗体SM17治疗特应性皮炎(AD)之临床前结果刊登于国际科学期刊《Allergy》
Apr 16, 2024 17:48 HKT
中國抗體SM17治療特應性皮炎(AD)之臨床前結果刊登於國際科學期刊《Allergy》
Apr 16, 2024 17:44 HKT
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy
Apr 16, 2024 17:35 HKT
Chiron AS in Trondheim, Norway, Has Developed The World's First Commercial Microplastic Reference Materials
Apr 09, 2024 22:30 HKT
中国生物制药(1177.HK)公布2023全年业绩
Mar 29, 2024 12:15 HKT
中國生物製藥(1177.HK)公布2023全年業績
Mar 29, 2024 12:09 HKT
Sino Biopharm (1177.HK) Announces 2023 Annual Results
Mar 29, 2024 11:45 HKT
Avance Clinical은 세계 백신 대회에서 최신 백신 임상시험 뉴스를 공유합니다. 이 중에는 HIV-1 연구도 포함됩니다
Mar 29, 2024 06:42 HKT
Avance Clinical將在世界疫苗大會上分享最新的疫苗臨床試驗新聞,包括HIV-1研究
Mar 29, 2024 06:33 HKT
Avance Clinical将在世界疫苗大会上分享最新的疫苗临床试验新闻,包括HIV-1研究
Mar 29, 2024 06:22 HKT
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
Mar 28, 2024 14:42 HKT
来自康希诺生物的亚洲首个流脑结合疫苗商业化取得巨大突破
Mar 27, 2024 21:48 HKT
來自康希諾生物的亞洲首個流腦結合疫苗商業化取得巨大突破
Mar 27, 2024 21:47 HKT
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough
Mar 27, 2024 21:46 HKT
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Mar 26, 2024 19:00 HKT
Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: